Shopping Cart
Remove All
Your shopping cart is currently empty
6-APDB
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T217787 Copy Product Info
🥰Excellent
6-APDB is a monoamine neurotransmitter releaser and monoamine transporter (Monoamine Transporter) modulator that selectively affects human monoamine transporters and partially agonizes the 5-HT2 receptor family. Its IC50 and Ki values for NET are 0.56 μM and 18 μM, respectively; for SERT, IC50 is 2.3 μM and Ki is 23 μM; and for DAT, IC50 is 33 μM and Ki is greater than 30 μM. In terms of rat and mouse TAAR1, 6-APDB exhibits Ki values of 1.0 μM and 0.21 μM, respectively. The compound inhibits norepinephrine and 5-HT reuptake and facilitates the release of three monoamine neurotransmitters, resulting in dose-dependent bidirectional locomotor effects in mice and complete substitution for the discriminative stimulus effects of MDMA. At high concentrations, 6-APDB shows no significant cytotoxicity and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behaviors linked to sporadic misuse.
6-APDB
Cas No. 152623-93-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | 6-APDB is a monoamine neurotransmitter releaser and monoamine transporter (Monoamine Transporter) modulator that selectively affects human monoamine transporters and partially agonizes the 5-HT2 receptor family. Its IC50 and Ki values for NET are 0.56 μM and 18 μM, respectively; for SERT, IC50 is 2.3 μM and Ki is 23 μM; and for DAT, IC50 is 33 μM and Ki is greater than 30 μM. In terms of rat and mouse TAAR1, 6-APDB exhibits Ki values of 1.0 μM and 0.21 μM, respectively. The compound inhibits norepinephrine and 5-HT reuptake and facilitates the release of three monoamine neurotransmitters, resulting in dose-dependent bidirectional locomotor effects in mice and complete substitution for the discriminative stimulus effects of MDMA. At high concentrations, 6-APDB shows no significant cytotoxicity and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behaviors linked to sporadic misuse. |
| In vitro | 6-APDB, at concentrations ranging from 1 nM to 100 μM over 10 minutes, inhibits the uptake of monoamines in HEK 293 cells expressing NET, DAT, and SERT, showing highest potency at NET, moderate at SERT, and lowest at DAT, resulting in a low DAT:SERT ratio, indicating a preference for serotonergic activity. At 100 μM for 45 or 15 minutes, it induces transporter-mediated release of norepinephrine, dopamine, and serotonin in HEK 293 cells expressing monoamine transporters. Additionally, 6-APDB acts as a low-potency partial agonist at the human 5-HT2A receptor and a high-potency partial agonist at the human 5-HT2B receptor within HEK 293 cells. |
| In vivo | 6-APDB administered to male Swiss-Webster mice (1-25 mg/kg; i.p.; single dose) induces a dose-dependent increase in locomotor activity, with an ED50 of 2.80 mg/kg. Higher doses initially suppress activity, followed by delayed excitation. In male Sprague-Dawley rats during drug discrimination trials, 6-APDB (0.25–2.5 mg/kg, i.p., single dose, 40-minute pretreatment) shows partial substitution effects for methamphetamine, cocaine, and DOM, and high doses reduce response rates. However, doses of 0.05-1 mg/kg completely substitute for MDMA's discriminative stimulus effect, with an ED50 of 0.21 mg/kg in trained male Sprague-Dawley rats. |
| Molecular Weight | 177.24 |
| Formula | C11H15NO |
| Cas No. | 152623-93-3 |
| Smiles | O1C2=CC(=CC=C2CC1)CC(N)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: 6-APDB in vivo | 6-APDB in vitro | 6-APDB formula | 6-APDB molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.